| TILRAY-PORTUGAL-UNIPESSOAL-LTD |
TILRAY-PORTUGAL-UNIPESSOAL-LTD |
85%
|
l supply chain facilities. InterCure’s EU-GMP manufacturing sites will import, register, and produce Cookies-branded products, including a future range of next-generation offerings such as live resin… |
| TLRY |
Tilray Brands, Inc. |
85%
|
Reciprocal relationship from TLRY graph: Reciprocal relationship from INCR graph: Reciprocal relationship from TLRY graph: Reciprocal relationship from INCR graph: l supply chain facilities. InterCur… |
| CGC |
Canopy Growth Corporation |
72%
|
luding all major pharmacies across Israel. The newly formed company, that will be held jointly by us and by Altman, focuses on the new Israeli CBD product market, following the Israeli Minister of He… |
| CGC |
Canopy Growth Corporation |
72%
|
Reciprocal relationship from CGC graph: Reciprocal relationship from INCR graph: luding all major pharmacies across Israel. The newly formed company, that will be held jointly by us and by Altman, fo… |
| XTLB |
XTL Biopharmaceuticals Ltd. |
72%
|
luding all major pharmacies across Israel. The newly formed company, that will be held jointly by us and by Altman, focuses on the new Israeli CBD product market, following the Israeli Minister of He… |
| XTLB |
XTL Biopharmaceuticals Ltd. |
72%
|
Reciprocal relationship from XTLB graph: Reciprocal relationship from INCR graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from INCR graph: luding all major pharmacies across … |
| AHUZA-PHARMACY-D-Y-LTD |
AHUZA-PHARMACY-D-Y-LTD |
62%
|
approval. Clinical trials that study pharmaceutical-grade cannabis for these purposes do not require preclinical studies or Phase 1 trials as a condition for the approval of Phase 2 trials. However, … |
| AURORA-CANNABIS-INC |
AURORA-CANNABIS-INC |
62%
|
luding all major pharmacies across Israel. The newly formed company, that will be held jointly by us and by Altman, focuses on the new Israeli CBD product market, following the Israeli Minister of He… |
| CANNASOUL-R-D-LTD |
CANNASOUL-R-D-LTD |
62%
|
ce cannabis out of Israel. In December 2020, we completed the first commercial export of our products, which consisted of several dozen kilograms, to the European Union as part of the Tilray Agreemen… |
| CARMA-HOLDCO-INC |
CARMA-HOLDCO-INC |
62%
|
ce cannabis out of Israel. In December 2020, we completed the first commercial export of our products, which consisted of several dozen kilograms, to the European Union as part of the Tilray Agreemen… |
| CLUB-PHARM-LTD |
CLUB-PHARM-LTD |
62%
|
approval. Clinical trials that study pharmaceutical-grade cannabis for these purposes do not require preclinical studies or Phase 1 trials as a condition for the approval of Phase 2 trials. However, … |
| COMPANY-INTERCURE-LTD |
COMPANY-INTERCURE-LTD |
62%
|
ares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable… |
| DORON-PHARMACY-LTD |
DORON-PHARMACY-LTD |
62%
|
approval. Clinical trials that study pharmaceutical-grade cannabis for these purposes do not require preclinical studies or Phase 1 trials as a condition for the approval of Phase 2 trials. However, … |
| F-O-R-E-BIOTHERAPEUTICS-LTD |
F-O-R-E-BIOTHERAPEUTICS-LTD |
62%
|
luding all major pharmacies across Israel. The newly formed company, that will be held jointly by us and by Altman, focuses on the new Israeli CBD product market, following the Israeli Minister of He… |
| GREENLOG-GLOBAL-LTD |
GREENLOG-GLOBAL-LTD |
62%
|
ares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable… |
| LEON-PHARM-LTD |
LEON-PHARM-LTD |
62%
|
approval. Clinical trials that study pharmaceutical-grade cannabis for these purposes do not require preclinical studies or Phase 1 trials as a condition for the approval of Phase 2 trials. However, … |
| MSMS-GREENLOG-GLOBAL-LTD |
MSMS-GREENLOG-GLOBAL-LTD |
62%
|
approval. Clinical trials that study pharmaceutical-grade cannabis for these purposes do not require preclinical studies or Phase 1 trials as a condition for the approval of Phase 2 trials. However, … |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
ares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable… |
| PHARMA-ZONE-LTD |
PHARMA-ZONE-LTD |
62%
|
ce cannabis out of Israel. In December 2020, we completed the first commercial export of our products, which consisted of several dozen kilograms, to the European Union as part of the Tilray Agreemen… |
| PHARMAZONE-PHARMACY-LTD |
PHARMAZONE-PHARMACY-LTD |
62%
|
vitch Chairman of the Board and CEO Amos Cohen CFO The accompanying notes are an integral part of the consolidated financial statements. F- 4 Intercure Ltd. Consolidated Statements of Profit or Loss … |
| PRAETORIAN-GLOBAL-INC |
PRAETORIAN-GLOBAL-INC |
62%
|
ce cannabis out of Israel. In December 2020, we completed the first commercial export of our products, which consisted of several dozen kilograms, to the European Union as part of the Tilray Agreemen… |
| SUPER-PHARM-LTD |
SUPER-PHARM-LTD |
62%
|
EVA) (TASE: TEVA), a leading Israeli company in the health services field (the “SLE Agreement”). Pursuant to the SLE Agreement, SLE provides us with logistics, storage, collection and distribution se… |
| TEL-AVIV-STOCK-EXCHANGE-CANNASOUL-R-D-LTD |
TEL-AVIV-STOCK-EXCHANGE-CANNASOUL-R-D-LTD |
62%
|
ce cannabis out of Israel. In December 2020, we completed the first commercial export of our products, which consisted of several dozen kilograms, to the European Union as part of the Tilray Agreemen… |
